ALRTFOTCSurgical & Medical Instruments & ApparatusUS GAAP · USD

ALR Technologies SG Ltd.

ALR Technologies SG Ltd. is a Singapore-based medical technology company focused on glucose-monitoring and digital diabetes-management solutions. Its business centers on connected continuous glucose monitoring products and related software platforms for people managing diabetes, with activity that includes commercialization across North American and other international markets.

Nettotulos−22,1milj. USD
−38,9 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

012345milj. USD2020: EBIT 3,8 milj. USD20202021: 0,01 milj. USD2021: EBIT 2,9 milj. USD20212022: 0,00 milj. USD2022: EBIT 4,3 milj. USD20222023: 0,03 milj. USD202320242025
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Human CGM systems60 %

Wearable glucose-monitoring products and related digital tools for diabetes management.

Veterinary CGM systems20 %

GluCurve Pet CGM offerings designed for glucose monitoring in animals.

Software and analytics20 %

Connected software, tracking, and data services that support glucose-monitoring workflows.

Asiakkaat

The company serves patients and caregivers who need glucose monitoring and digital diabetes-management tools, with use cases spanning both human and pet health. Its products are also relevant to clinicians, distributors, and channel partners that help bring monitoring solutions to end users. The launch of pet CGM indicates an additional veterinary end market alongside traditional diabetes-care users.

Diabetes patients

Buy CGM devices and related software to track glucose trends and support day-to-day management.

Caregivers and family users

Use connected monitoring tools to observe readings and manage diabetes for another person.

Veterinary market

Purchases GluCurve Pet CGM products for glucose monitoring in companion animals.

Clinics and care providers

Adopt the platform to support monitoring, review data, and manage patient workflows.

Distributors and resellers

Buy products for channel distribution and market expansion in target geographies.

Strategia

The company’s strategy appears centered on commercializing its glucose-monitoring platform and extending it into adjacent use cases such as pet CGM. Launching products in new markets suggests a priority on geographic expansion and channel development rather than a single-home-market model. Building a connected device-and-software offering can increase customer stickiness and create a broader digital health platform around monitoring data.

Commercialize GluCurve products in additional marketsLyhyt aikaväli

Broader market access increases the installed base and reduces reliance on a single geography.

Build a connected diabetes-management platformKeskipitkä aikaväli

Software and data services can strengthen recurring customer engagement around the device.

Extend into veterinary monitoringKeskipitkä aikaväli

Adjacency to pet health can open a differentiated niche and broaden the addressable market.

Maantiede

2025

ALR Technologies SG Ltd. is headquartered in Singapore, while the available filing shows principal executive-office activity in Singapore and disclosure to U.S. markets through SEC reporting. The company’s business is oriented toward international commercialization, including a stated product launch in Canada, which suggests a North American market focus for certain products. Its geography matters because medical-device commercialization, regulatory approvals, and channel access can differ significantly by country.

Singapore100 %

Riskit

The business depends on regulatory acceptance, product performance, and channel execution in a highly competitive medical-device market. Because its products span connected hardware and software, it also faces risks around adoption, reimbursement, supply continuity, and cross-border commercialization. Expansion into new geographies and new end markets can create additional execution risk if product claims, approvals, or distribution are delayed.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Competitive pressure1Regulatory approval and compliance risk2Commercial adoption risk3Execution risk in new geographies4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Competitive pressureVaikutus: KorkeaTodennäköisyys: Korkea

    The diabetes-monitoring market is crowded and larger incumbents can outspend on distribution and product development.

    Kohdistuu: CGM devices and digital diabetes tools

  2. Regulatory approval and compliance riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Glucose-monitoring devices must meet country-specific medical-device rules before commercialization.

    Kohdistuu: New market launches such as Canada

  3. Commercial adoption riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Customers may delay switching to a new CGM platform if accuracy, usability, or support are not compelling.

    Kohdistuu: Human CGM and pet CGM products

  4. Execution risk in new geographiesVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Launching in new countries requires local regulatory, logistics, and channel capabilities.

    Kohdistuu: Canada and other international markets

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition

Device sales, software access, and bundled offerings may have different timing and allocation rules.

Vaikutus: Can shift reported revenue between periods

Inventory valuation

Medical-device inventory can become obsolete if product specs, approvals, or demand change.

Vaikutus: Can affect gross profit and working capital

Intangible asset impairment

Product platforms and launch-related intangibles may need write-downs if commercialization lags.

Vaikutus: Can create non-cash charges

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 28.9.2026

ALR Technologies SG Ltd. (OTC) – Surgical & Medical Instruments & Apparat | Analyysi – Clarifo